Literature DB >> 33814109

Effectiveness of frailty screening and perioperative team management of colectomy patients aged 80 years or more.

Yozo Suzuki1, Mitsuyoshi Tei2, Masahisa Ohtsuka3, Manabu Mikamori3, Kenta Furukawa3, Mitsunobu Imasato3, Rie Oe4, Masahiro Tanemura5, Takashi Kita6, Hiroki Akamatsu3.   

Abstract

BACKGROUND: We aimed to clarify usefulness of the modified Frailty Index 11 (mFI-11) for assessing risk of postoperative complications (POCs) and effectiveness of perioperative management team (POMT) intervention for improving postoperative status of frail aged patients requiring colorectal cancer (CRC) surgery.
METHODS: We compared, retrospectively, surgical outcomes among 151 consecutive CRC surgery patients aged ≥80 years. Patients were grouped by mFI-11 scores and by POMT intervention (vs. no POMT intervention).
RESULTS: POCs were more prevalent, postoperative stays were longer, and discharge status was poorer among high-risk (mFI-11 ≥ 3/11) patients without POMT intervention than among low-risk (mFI-11 ≤ 2/11) patients (p = 0.04, p = 0.02, p < 0.01). Multiple POCs occurred less frequently and performance of activities of daily living was better for high-risk patients with (vs. those without) POMT intervention (p = 0.04, p = 0.03).
CONCLUSION: POMT intervention appears beneficial for frail aged patients scheduled for CRC surgery.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADL; Colectomy; Colorectal cancer; Frailty; Team intervention

Mesh:

Year:  2021        PMID: 33814109     DOI: 10.1016/j.amjsurg.2021.03.059

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  The prevalence and prognostic value of frailty screening measures in patients undergoing surgery for colorectal cancer: observations from a systematic review.

Authors:  Josh McGovern; Ross D Dolan; Paul G Horgan; Barry J Laird; Donald C McMillan
Journal:  BMC Geriatr       Date:  2022-03-29       Impact factor: 3.921

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.